Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05780268
Other study ID # 014/ACTIV-3/H1
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date August 5, 2020
Est. completion date February 1, 2021

Study information

Verified date December 2023
Source National Institute of Allergy and Infectious Diseases (NIAID)
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study looks at the safety and effectiveness of LY3819253 in treating COVID-19 in people who have been hospitalized with the infection. Participants in the study will be treated with either LY3819253 plus current standard of care (SOC), or with placebo plus current SOC. This is ACTIV-3/TICO Treatment Trial H1.


Description:

This is a treatment trial of the ACTIV-3/TICO master protocol (NCT04501978) to evaluate the safety and efficacy of LY3819253 in hospitalized patients infected with COVID-19. This is a randomized, blinded, controlled sub-study of LY3819253 plus current standard of care (SOC) against placebo plus current SOC. The placebo arm may be shared across other sub-studies of the ACTIV-3/TICO master protocol. When more than one drug is being tested at the same time, participants will be randomly allocated to treatments or placebo. Randomization will be stratified by study site pharmacy and disease severity. There are 2 disease severity strata: Participants without organ failure (severity stratum 1) and participants with organ failure (severity stratum 2). An independent Data and Safety Monitoring Board (DSMB) will regularly review interim analyses and summarize safety and efficacy outcomes. The pace of enrollment with be initially restricted, and there will be an early review of safety data by the DSMB. At the outset of the trial, only participants in disease severity stratum 1 will be enrolled. This will continue until approximately 300 participants are enrolled and followed for 5 days. The exact number will vary according to the speed of enrollment and the timing of DSMB meetings. Prior to expanding enrollment to also include patients in disease severity stratum 2, safety will be evaluated and a pre-specified futility assessment by the DSMB will be carried out using 2 ordinal outcomes assessed at Day 5. If LY3819253 passes the futility assessment, enrollment of participants will be expanded, seamlessly and without any data unblinding, to include participants in disease severity stratum 2 as well as those in disease severity stratum 1. Future interim analyses will be based on the primary endpoint of sustained recovery and will use pre-specified guidelines to determine early evidence of benefit, harm, or futility for the investigational agent. Participants will be followed for 18 months following randomization. This trial will be conducted in several hundred clinical sites. Participating sites are affiliated with networks funded by the United States National Institutes of Health (NIH) and the US Department of Veterans Affairs.


Recruitment information / eligibility

Status Completed
Enrollment 314
Est. completion date February 1, 2021
Est. primary completion date February 1, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: Refer to the master protocol (NCT04501978) Exclusion Criteria: Refer to the master protocol (NCT04501978) Additional Criteria: Non-pregnant female participants who are of reproductive potential and male participants who are able to father a child must abstain from male/female sexual intercourse or agree to use two forms of effective contraception, where at least one form is highly effective (less than 1% failure rate), for the entirety of the study and for 90 days after investigational agent is administered. Highly effective methods of contraception (less than 1% failure rate) include, but are not limited to: - combination oral contraceptives - implanted contraceptives - intrauterine devices Effective methods of contraception include, but are not limited to: - diaphragms and cervical caps with spermicide - cervical sponges - condoms with spermicide NOTE: - Use of male and female condoms as a double barrier method is not considered acceptable due to the high failure rate when these barrier methods are combined. - Barrier protection methods without concomitant use of a spermicide are not an effective or acceptable method of contraception. - Periodic abstinence (e.g., calendar, ovulation, symptothermal, postovulation methods), and withdrawal are not acceptable methods of contraception. Participants not of reproductive potential are eligible without requiring the use of a contraceptive method. Participant-reported history is acceptable documentation of surgical sterilization and menopause. Participants with pregnant partners should use condoms during vaginal intercourse through 90 days after investigational agent administration. Participants should refrain from sperm donation through 90 days after investigational agent administration. NOTE: Reproductive potential is defined as patients who have reached menarche, who have not been post-menopausal for at least 12 consecutive months with follicle-stimulating hormone (FSH) = 40 IU/ml or 24 consecutive months if an FSH is not available, who have not undergone surgical sterilization, who do not have other clinical condition that could induce amenorrhea, who are not taking medications such as oral contraceptives, hormones, gonadotropin releasing hormone, antiestrogens, selective estrogen receptor modulators (SERMs) or chemotherapy that could induce amenorrhea. Individuals with permanent infertility due to an alternate medical cause (e.g. Mullerian agenesis, androgen insensitivity), investigator discretion should be applied.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
LY3819253
LY3819253 is a neutralizing immunoglobulin G (IgG)-1 monoclonal antibody (mAb) to the receptor binding domain (RBD) of the S protein of SARS-CoV-2
Placebo
Commercially available 0.9% sodium chloride solution
Remdesivir
Antiviral agent

Locations

Country Name City State
Denmark Aalborg Hospital (Site 625-005), Hobrovej 18 Aalborg
Denmark Aarhus Universitetshospital, Skejby (Site 625-002), Department of Infectious Diseases, Palle Juul-Hensens Boulevard 99 Aarhus N
Denmark Righospitalet (Site 625-006), Blegdamsvej 9, Copenhagen Ø
Denmark Herlev/Gentofte Hospital (Site 625-012), Medicinsk Afdeling, Herlev Ringvej 75 Herlev
Denmark Nordsjællands Hospital (Site 625-009), Dyrehavevej 29 Hillerød
Denmark Hvidovre University Hospital, Department of Infectious Diseases (Site 625-001), Kettegård allé 30 Hvidovre
Denmark Kolding Sygehus (Site 625-011), Medicinsk Afdeling, Sygehusvej 24 Kolding
Denmark Odense University Hospital (Site 625-004), Infektionsmedicinsk Forskningsenhed, J.B. Winsløwsgade 4 Odense
Singapore Tan Tock Seng Hospital (Site 612-201), National Centre for Infectious Diseases (NCID), 11 Jalan Tan Tock Seng Singapore
Spain Hospital Universitari Germans Trias i Pujol (Site 626-003), Infectious Disease Unit, Second Floor, Building Maternal, Road Canyet s/n Badalona Barcelona
Spain Hospital Clínic de Barcelona (Site 626-004), Carrer de Villaroel 170 Barcelona
Spain Hospital Del Mar (Site 626-025), Paseo Maritimo 25-29 Barcelona
Spain Hospital Clínico San Carlos (Site 626-017), Enfermedades infecciosas, C/Martin Lagos CN Madrid
Spain Hospital General Universitario Gregorio Marañón (Site 626-001), Dr. Esquerdo, 46 Madrid
Spain UCICEC (Clinical Trial Unit) Hospital Universitario La Paz (Site 626-012), Paseo de la Castellana 261, 2a planta Hospital Maternal Madrid
United States University of Michigan (Site 205-001), 1500 East Medical Center Drive Ann Arbor Michigan
United States Emory University (Site 301-008), The Emory Clinic, Bldg. A, Suite 2236, 1365 Clifton Rd., NE Atlanta Georgia
United States University of Colorado Hospital (Site 204-001), 12605 E. 16th Avenue Aurora Colorado
United States University of Maryland Medical Center (Site 301-019), 22 South Greene Street Baltimore Maryland
United States Massachusetts General Hospital (Site 202-002), 55 Fruit Street Boston Massachusetts
United States Montefiore Medical Center Moses Hospital (Site 206-001), 111 E. 210th Street Bronx New York
United States Montefiore Medical Center Weiler Hospital (Site 206-003), 1825 Eastchester Road Bronx New York
United States University of Virginia Health Systems (Site 301-021), 1215 Lee Street Charlottesville Virginia
United States Cleveland Clinic Fairview Hospital (Site 207-005), 18101 Lorain Avenue Cleveland Ohio
United States Cleveland Clinic Foundation (Site 207-001), 9500 Euclid Avenue Cleveland Ohio
United States Baylor, Scott and White Health (Site 301-003), Baylor University Medical Center, 3500 Gaston Ave. Dallas Texas
United States UT Southwestern Medical Center (Site 084-001), 1936 Amelia Court, 2nd Floor Dallas Texas
United States Denver Public Health (Site 017-004), 660 Bannock St., MC2600 (Infectious Disease Clinic) Denver Colorado
United States Henry Ford Health System, Henry Ford Hospital (Site 014-001), 2799 W. Grand Blvd. Detroit Michigan
United States Duke University Hospital (Site 301-006), 2301 Erwin Road Durham North Carolina
United States Community Regional Medical Center (Site 203-005), 2823 Fresno Street Fresno California
United States Cleveland Clinic Marymount Hospital (Site 207-006), 12300 McCraken Road Garfield Heights Ohio
United States Memorial Hermann Hospital (Site 203-006), 6411 Fannin Street Houston Texas
United States Michael E. DeBakey Veterans Affairs Medical Center (MEDV AMC) (Site 074-006), 2002 Holcombe Blvd. Houston Texas
United States University of Mississippi Medical Center (Site 202-005), 2500 North State Street Jackson Mississippi
United States Dartmouth-Hitchcock Medical Center/Mary Hitchcock Memorial Hospital (Site 301-024), One Medical Center Drive Lebanon New Hampshire
United States University of Kentucky Hospital (Site 210-004), 1000 South Limestone St. Lexington Kentucky
United States Keck Hospital of USC (Site 301-020), 1500 San Pablo Street Los Angeles California
United States Miami VAMC (Site 074-003), 1201 NW 16 Street Miami Florida
United States Hennepin Healthcare (Site 027-001), 701 Park Avenue Minneapolis Minnesota
United States West Virginia University (Site 301-023), One Medical Center Drive Morgantown West Virginia
United States Intermountain Medical Center (Site 211-001), 5121 South Cottonwood Street Murray Utah
United States Vanderbilt University Medical Center (Site 212-001), 1211 Medical Center Drive Nashville Tennessee
United States Ochsner Clinic Foundation (Site 301-015), 1514 Jefferson Highway New Orleans Louisiana
United States Oregon Health & Science University (Site 208-003), 3181 SW Sam Jackson Park Rd. Portland Oregon
United States Virginia Commonwealth University Health System (Site 210-005), 1250 East Marshall Street Richmond Virginia
United States University of Utah Hospital (Site 211-002), 419 Wakara Way, Suite 207 Salt Lake City Utah
United States San Francisco VAMC (Site 074-002), 4150 Clement St. San Francisco California
United States UCSF Medical Center (Site 203-001), Moffitt-Long Hospital, 505 Parnassus Ave. San Francisco California
United States UCSF Medical Center at Mount Zion (Site 203-007), 1600 Divisadero St. San Francisco California
United States Harborview Medical Center (Site 208-001), 325 9th Avenue Seattle Washington
United States University of Washington Medical Center - Montlake (Site 208-006), 1959 NE Pacific Street Seattle Washington
United States Baystate Medical Center (Site 201-001), 759 Chestnut Street Springfield Massachusetts
United States Stanford University Hospital & Clinics (Site 203-003), 300 Pasteur Dr. Stanford California
United States Banner University Medical Center Tucson (Site 206-004), 1625 N. Campbell Avenue Tucson Arizona
United States MedStar Georgetown University Hospital (Site 067-001), 3800 Reservoir Road NW Washington District of Columbia
United States Wake Forest University Health Sciences (Site 210-001), Medical Center Blvd Winston-Salem North Carolina

Sponsors (13)

Lead Sponsor Collaborator
National Institute of Allergy and Infectious Diseases (NIAID) AIDS Clinical Trials Group, Cardiothoracic Surgical Trials Network, Eli Lilly and Company, International Network for Strategic Initiatives in Global HIV Trials (INSIGHT), Kirby Institute, Medical Research Council, National Heart, Lung, and Blood Institute (NHLBI), Prevention and Early Treatment of Acute Lung Injury, University of Copenhagen, University of Minnesota, US Department of Veterans Affairs, Washington D.C. Veterans Affairs Medical Center

Countries where clinical trial is conducted

United States,  Denmark,  Singapore,  Spain, 

References & Publications (1)

ACTIV-3/TICO LY-CoV555 Study Group; Lundgren JD, Grund B, Barkauskas CE, Holland TL, Gottlieb RL, Sandkovsky U, Brown SM, Knowlton KU, Self WH, Files DC, Jain MK, Benfield T, Bowdish ME, Leshnower BG, Baker JV, Jensen JU, Gardner EM, Ginde AA, Harris ES, — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants With Sustained Recovery Sustained recovery defined as being discharged from the index hospitalization, followed by being alive and home for 14 consecutive days prior to Day 90. Through Day 90
Primary Number of Participants With an Ordinal Outcome on Day 5 Ordinal outcome with 7 mutually exclusive categories Status on Day 5
Secondary Number of Participants Who Died From All Causes All-cause mortality Through Day 90
Secondary Number of Participants With a Safety Outcome Through Day 5 Death, SAE, clinical organ failure, serious infections, or Grade 3 or 4 event through Day 5 Through Day 5
Secondary Number of Participants With a Safety Outcome Through Day 28 Death, SAE, clinical organ failure, serious infections, or Grade 3 or 4 event through Day 28 Through Day 28
Secondary Number of Participants With a Safety Outcome Through Day 90 Death, SAE, clinical organ failure, serious infections through Day 90 Through Day 90
See also
  Status Clinical Trial Phase
Withdrawn NCT06065033 - Exercise Interventions in Post-acute Sequelae of Covid-19 N/A
Completed NCT06267534 - Mindfulness-based Mobile Applications Program N/A
Completed NCT05047601 - A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection Phase 2/Phase 3
Recruiting NCT05323760 - Functional Capacity in Patients Post Mild COVID-19 N/A
Recruiting NCT04481633 - Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection N/A
Completed NCT04537949 - A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults Phase 1/Phase 2
Completed NCT04612972 - Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) to Prevent COVID-19 in Healthy Adult Population In Peru Healthy Adult Population In Peru Phase 3
Recruiting NCT05494424 - Cognitive Rehabilitation in Post-COVID-19 Condition N/A
Active, not recruiting NCT06039449 - A Study to Investigate the Prevention of COVID-19 withVYD222 in Adults With Immune Compromise and in Participants Aged 12 Years or Older Who Are at Risk of Exposure to SARS-CoV-2 Phase 3
Enrolling by invitation NCT05589376 - You and Me Healthy
Completed NCT05158816 - Extracorporal Membrane Oxygenation for Critically Ill Patients With COVID-19
Recruiting NCT04341506 - Non-contact ECG Sensor System for COVID19
Completed NCT04512079 - FREEDOM COVID-19 Anticoagulation Strategy Phase 4
Completed NCT04384445 - Zofin (Organicell Flow) for Patients With COVID-19 Phase 1/Phase 2
Completed NCT05975060 - A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants. Phase 2/Phase 3
Active, not recruiting NCT05542862 - Booster Study of SpikoGen COVID-19 Vaccine Phase 3
Terminated NCT05487040 - A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease Phase 1
Withdrawn NCT05621967 - Phonation Therapy to Improve Symptoms and Lung Physiology in Patients Referred for Pulmonary Rehabilitation N/A
Terminated NCT04498273 - COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80 Phase 3
Active, not recruiting NCT06033560 - The Effect of Non-invasive Respiratory Support on Outcome and Its Risks in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2)-Related Hypoxemic Respiratory Failure